Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

mRNA Vaccine Effectiveness Against COVID-19 Hospitalization Among Solid Organ Transplant Recipients. The Journal of infectious diseases Kwon, J. H., Tenforde, M. W., Gaglani, M., Talbot, H. K., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Casey, J. D., Mohr, N. M., Zepeski, A., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Caspers, S. D., Exline, M. C., Botros, M., Gong, M. N., Li, A., Mohamed, A., Johnson, N. J., Srinivasan, V., Steingrub, J. S., Peltan, I. D., Brown, S. M., Martin, E. T., Khan, A., Hough, C. L., Busse, L. W., Duggal, A., Wilson, J. G., Perez, C., Chang, S. Y., Mallow, C., Rovinski, R., Babcock, H. M., Lauring, A. S., Felley, L., Halasa, N., Chappell, J. D., Grijalva, C. G., Rice, T. W., Womack, K. N., Lindsell, C. J., Hart, K. W., Baughman, A., Olson, S. M., Schrag, S., Kobayashi, M., Verani, J. R., Patel, M. M., Self, W. H., Influenza and Other Viruses in the Acutely Ill (IVY) Network 2022

Abstract

BACKGROUND: The study objective was to evaluate 2 and 3 dose COVID-19 mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among adult solid organ transplant (SOT) recipients.METHODS: 21-site case-control analysis of 10,425 adults hospitalized March-December 2021. Cases were hospitalized with COVID-19; controls were hospitalized for an alternative diagnosis (SARS-CoV-2 negative). Participants were classified as: SOT recipient (n=440), other immunocompromising condition (n=1684), or immunocompetent (n=8301). VE against COVID-19 associated hospitalization was calculated as 1-adjusted odds ratio of prior vaccination among cases compared with controls.RESULTS: Among SOT recipients, VE was 29% (95% CI: -19 to 58%) for 2 doses and 77% (95% CI: 48 to 90%) for 3 doses. Among patients with other immunocompromising conditions, VE was 72% (95% CI: 64 to 79%) for 2 doses and 92% (95% CI: 85 to 95%) for 3 doses. Among immunocompetent patients, VE was 88% (95% CI: 87 to 90%) for 2 doses and 96% (95% CI: 83 to 99%) for 3 doses.CONCLUSION: Effectiveness of COVID-19 mRNA vaccines was lower for SOT recipients than immunocompetent people and those with other immunocompromising conditions. Among SOT recipients, vaccination with 3 doses of an mRNA vaccine led to substantially greater protection than 2 doses.

View details for DOI 10.1093/infdis/jiac118

View details for PubMedID 35385875